NCT06256276

Brief Summary

Recent studies suggest that patients with heart failure (HF) may have a reduced ability to control the tone of their blood vessels, heart rate or blood pressure in response to stress. This study will test whether 16 weeks of protein supplements can improve control of blood pressure and heart rate in HF patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for not_applicable heart-failure

Timeline
Completed

Started Jul 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 26, 2016

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 11, 2018

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2018

Completed
6 years until next milestone

First Submitted

Initial submission to the registry

February 2, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 13, 2024

Completed
Last Updated

February 13, 2024

Status Verified

January 1, 2024

Enrollment Period

1.5 years

First QC Date

February 2, 2024

Last Update Submit

February 12, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Cardiovascular assessment of blood pressure

    Measuring orthostatic blood pressure

    Change from baseline to 16 weeks

  • Cardiovascular assessment

    Measuring heart rate before and after intervention

    Change from baseline to 16 weeks

Study Arms (2)

Whey protein powder and L-carnitine capsules

EXPERIMENTAL

Subjects will daily consume whey protein powder to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) L-carnitine for 16 weeks.

Dietary Supplement: Whey protein powder and L-carnitine

Maltodextrin placebo powder and Psyllium Husk capsules

PLACEBO COMPARATOR

Subjects will daily consume maltodextrin powder as if to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) psyllium husk for 16 weeks.

Dietary Supplement: Maltodextrin placebo powder and Psyllium Husk capsules

Interventions

Dietary supplement intervention for 16 weeks

Also known as: Dymatize Elite Whey, Europa Sports Products
Whey protein powder and L-carnitine capsules

Maltodextrin placebo powder and Psyllium Husk capsules

Maltodextrin placebo powder and Psyllium Husk capsules

Eligibility Criteria

Age60 Years - 90 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Mild to moderate heart failure (NYHA I, II, or III symptomology) as confirmed by study physician

You may not qualify if:

  • Moderately-severe dementia (MoCA score)
  • Active inflammatory bowel disease
  • Active cancer or chemotherapy in the past year
  • Self-reported allergy to whey protein
  • Documented insulin-dependent diabetes mellitus, or uncontrolled diabetes with hemoglobin A1C \>8.5% (collected from medical record)
  • \>50mg doses of metoprolol or atenolol daily or more than 12.5mg twice daily of carvedilol
  • History of renal failure stage IV or V
  • History of severe orthostasis (\>20mm Hg drop in systolic pressure)
  • History of high grade second degree heart block
  • History of arrhythmias (atrial or ventricular, tachy or brady)
  • Other criteria as determined by the study physician

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

Location

MeSH Terms

Conditions

Heart Failure

Interventions

CarnitinePsyllium

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Trimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsPlant ExtractsPlant PreparationsBiological ProductsComplex Mixtures

Study Officials

  • Gohar Azhar, M.D.

    University of Arkansas

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 2, 2024

First Posted

February 13, 2024

Study Start

July 26, 2016

Primary Completion

January 11, 2018

Study Completion

February 1, 2018

Last Updated

February 13, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations